Could the Shingles Vaccine Help Protect Against Dementia?

Recent studies suggest a potential link between the shingles vaccine and a lower risk of developing dementia, sparking a surge in demand across pharmacies in the UK. Research from Stanford University and Oxford University has shown promising correlations, though experts emphasize that further clinical trials are needed to prove a direct causal relationship.

The Stanford and Oxford Studies

A prominent study conducted at Stanford University and published last year utilized a vaccination policy change in Wales. By comparing groups of people of very similar ages who differed only in their eligibility for the shingles vaccine, researchers tracked participants over seven years. The findings indicated that those eligible for the vaccine had roughly a 20% lower rate of new dementia diagnoses, with a particularly pronounced effect observed among women.

Additional research led by Oxford University scientists and published in Nature Medicine examined medical records of over 200,000 Americans. The study compared recipients of the older Zostavax vaccine with those who received the newer Shingrix vaccine. Results showed that Shingrix recipients experienced a lower rate of dementia diagnoses and gained an average of 164 additional dementia-free days during the follow-up period.

"While the findings are encouraging, it is still too early to recommend the vaccine specifically for dementia prevention," note experts from Alzheimer's Research UK.

Shingles and Brain Health

Shingles is caused by the reactivation of the varicella-zoster virus, the same virus responsible for chickenpox. After recovery, the virus remains dormant in nerve cells and can reactivate later in life when the immune system weakens. Researchers hypothesize that the viral reactivation triggers inflammatory processes affecting the nervous system, potentially contributing to neurodegenerative conditions like Alzheimer's disease.

Preventing the virus from reactivating through vaccination might theoretically reduce these inflammatory pathways. However, exact biological mechanisms remain unclear, and current medical guidelines do not endorse using the vaccine solely for cognitive protection.

Current Recommendations and Access

In Israel, the Shingrix vaccine is officially recommended for adults aged 50 and older, as well as for immunocompromised individuals from age 18. It is included in the national health basket for seniors 65 and older and specific risk groups, subject to co-pays. Medical professionals reiterate that established methods for reducing cognitive decline remain paramount, including regular physical activity, a balanced diet, blood pressure control, and social engagement.